Department of Urology & Department of Immunology, Roswell Park CancerInstitute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Metastatic renal cell carcinoma (mRCC) is a lethal disease. The advent of tyrosine kinase inhibitors (TKIs) has changed the disease process, yet the majority of patients will develop treatment-resistant disease. IL-2 based immunotherapy in mRCC is the only US FDA-approved treatment with curative results. Immunotherapeutic vaccine approaches to mRCC have been under investigation for several decades with mixed results. The recent FDA-approval of the first cellular immunotherapy in prostate cancer (Provenge®) has reinvigorated the search for similar vaccines approaches in mRCC. This review introduces the concepts and different features required for a successful anticancer vaccine approach.
Written by:
Schwaab T, Ernstoff MS. Are you the author?
Reference: Therapy. 2011 Jul;4(8):369-377.
PubMed Abstract
PMID: 21869865
UroToday.com Renal Cancer Section
